Why and how to use insulin therapy earlier in the management of type 2 diabetes

被引:14
作者
Meneghini, Luigi [1 ]
机构
[1] Univ Miami, Miller Sch Med, Eleanor & Joseph Kosow Diabet Treatment Ctr, Diabet Res Inst, Miami, FL 33136 USA
关键词
type; 2; diabetes; insulin; analogs; hypoglycemia;
D O I
10.1097/SMJ.0b013e31802ed2ea
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most patients with type 2 diabetes are inadequately controlled on their current therapy. Suboptimal glycemic control can have devastating consequences, such as retinopathy, nephropathy, neuropathy, and cardiovascular disease that may ultimately lead to mortality. Most patients eventually need insulin therapy, and initiating insulin earlier in the course of type 2 diabetes may lead to optimal glycemic control and prevent or delay diabetes-related complications. Although insulin therapy is the most effective method of managing hyperglycemia, it is often delayed owing to concerns about the complexity and inconvenience of treatment regimens; fear of injections, hypoglycemia or weight gain; and the time required to learn how to effectively manage insulin therapy. The development of insulin analogs, biphasic insulin analogs, and more convenient insulin delivery systems may make insulin therapy more manageable and help more patients achieve their treatment goals.
引用
收藏
页码:164 / 174
页数:11
相关论文
共 109 条
[1]   Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes [J].
Abraira, C ;
Colwell, J ;
Nuttall, F ;
Sawin, CT ;
Henderson, W ;
Comstock, JP ;
Emanuele, NV ;
Levin, SR ;
Pacold, I ;
Lee, HS ;
Silbert, CK ;
Cxypoliski, R ;
Vasquez, M ;
Kernan, D ;
Niewoehner, C ;
Backes, M ;
Bradley, M ;
Bradley, M ;
Crow, R ;
Rubino, F ;
Bushnell, D ;
Pfeifer, M ;
Service, FJ ;
Howard, B ;
Chew, E ;
Hoogwerf, B ;
Seigel, D ;
Clark, CM ;
Olefsky, JM ;
Porte, D ;
Sussman, KE ;
Johnson, N ;
Christine, B ;
Tir, K ;
Sather, M ;
Day, P ;
Morgan, N ;
Deykin, D ;
Gold, J ;
Huang, P .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) :181-188
[2]   Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients [J].
Alvarsson, M ;
Sundkvist, G ;
Lager, I ;
Henricsson, M ;
Berntorp, K ;
Fernqvist-Forbes, E ;
Steen, L ;
Westermark, G ;
Westermark, P ;
Örn, T ;
Grill, V .
DIABETES CARE, 2003, 26 (08) :2231-2237
[3]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[4]   INSULIN THERAPY IN OBESE, NON-INSULIN-DEPENDENT DIABETES INDUCES IMPROVEMENTS IN INSULIN ACTION AND SECRETION THAT ARE MAINTAINED FOR 2 WEEKS AFTER INSULIN WITHDRAWAL [J].
ANDREWS, WJ ;
VASQUEZ, B ;
NAGULESPARAN, M ;
KLIMES, I ;
FOLEY, J ;
UNGER, R ;
REAVEN, GM .
DIABETES, 1984, 33 (07) :634-642
[5]  
[Anonymous], 2005, GLOB GUID TYP 2 DIAB
[6]  
[Anonymous], 2004, J PHARM PRACT, DOI DOI 10.1177/0897190003261304
[7]   Safety and side effects of the insulin analogues - Response [J].
Bain, Stephen C. ;
Kamal, Ali D. .
EXPERT OPINION ON DRUG SAFETY, 2006, 5 (03) :349-350
[8]   Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c [J].
Bastyr, EJ ;
Stuart, CA ;
Brodows, RG ;
Schwartz, S ;
Graf, CJ ;
Zagar, A ;
Robertson, KE .
DIABETES CARE, 2000, 23 (09) :1236-1241
[9]   A LONG-TERM, RANDOMIZED, COMPARATIVE-STUDY OF INSULIN VERSUS SULFONYLUREA THERAPY IN TYPE-2 DIABETES [J].
BIRKELAND, KI ;
HANSSEN, KF ;
URDAL, P ;
BERG, K ;
VAALER, S .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (03) :305-313
[10]  
Boehm Bernhard O, 2004, Eur J Intern Med, V15, P496, DOI 10.1016/j.ejim.2004.10.001